Learning and memory in transgenic mice modeling Alzheimer's disease

Learning and Memory

Volumn 8, Issue 6, 2001, Pages 301-308

  Ashe, K H ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN;

AGING; ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; COGNITIVE DEFECT; DISEASE MODEL; LEARNING; MEMORY; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; REVIEW; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LEARNING; MEMORY; MICE; MICE, TRANSGENIC;

EID: 0035674312     PISSN: 10720502     EISSN: None     Source Type: Journal    
DOI: 10.1101/lm.43701     Document Type: Review

References (52)

1. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes
2. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
3. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
4. The mean Aβ load in the hippocampus correlates with duration and severity of dementia in subgroups of Alzheimer disease
5. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older
6. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects
7. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice
8. Genes, models and Alzheimer's disease
9. A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease
10. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice
11. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of APP695
12. Immunization against Aβ in APP-overexpressing transgenic mice
13. β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease
14. Large amounts of neocortical β A4 deposits without neuritic plaques nor tangles in a psychometrically assessed, non-demented person
15. Identification of normal and pathological aging in prospectively studied nondemented elderly humans
16. Behavioral deficits in APP(V717F) transgenic mice deficient for the apolipoprotein E gene
17. Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain
18. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein
19. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician
20. Alzheimer-type neuropathology in tnansgenic mice overexpressing V717F β-amyloid precursor protein
21. Correlation between cognitive deficits and Aβ deposits in transgenic APP+PS1 mice
22. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons
23. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: Lack of association with amyloid deposits
24. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models
25. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins
26. Correlative memory deficits. Aβ elevation, and amyloid plaques in transgenic mice
27. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
28. A β peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
29. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease
30. Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques
31. Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease
32. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease
33. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins
34. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
35. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease
36. Cognitive test performance in detecting, staging, and tracking Alzheimer's disease
37. Expression in brain of amyloid precursor protein mutated in the α-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice
38. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain
39. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein
40. A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
41. The Clinical Dementia Rating (CDR): Current version and scoring rules
42. High-level neuronal expression of aβ: 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation
43. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline
44. Adaptation of the circular platform spatial memory task for mice: Use in detecting cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease
45. Tau is a candidate gene for chromosome 17 frontotemporal dementia
46. Formation of beta-amyloid protein deposits in brains of transgenic mice
47. Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease
48. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
49. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
50. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment
51. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging
52. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease